AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01723332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational
Description: The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions.
Study NCT00882947 — intervention group
Intervention type: DRUG
Intervention: Ventavis (Iloprost, BAYQ6256)
Description: Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
Study NCT01723332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management
Description: The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions.
Study NCT04663048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PiXL
Description: Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
Study NCT04663048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PiXL
Description: Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
Study NCT01786967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine Fumarate
Description: FDA approved anticholinergic medication used for treatment of urge urinary incontinence
Study NCT02466022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Bolus dose prior to spinal anesthetic
Study NCT02466022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: Intrathecal hyperbaric bupivicaine 12.75mg
Study NCT02466022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivicaine
Description: Intrathecal hyperbaric bupivicaine 12.75mg
Study NCT02466022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Bolus 0.1cc/kg Normal Saline over 10 min
Study NCT02300662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
Study NCT04476693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Description: Consumption of breakfast: The breakfast provided was designed based on the characteristics of an ideal breakfast outlined in Giovannini et al., (2008). The breakfast provided in the present study will include the following: all-bran cereals (Kellogg's), semi-skimmed milk (Tesco), Royal Gala Apple (Tesco) and Orange Juice from Concentrate (Tesco) containing the amount of carbohydrates usually consumed at breakfast in the UK (Reeves et al., 2013). The portion for each participant will contain 0.06 g of carbohydrate per kcal of measured RMR. As the portion size (20% of daily calorie intake) will be calculated based on individual RMR , no leftovers will be allowed.
Study NCT04476693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Omission
Description: Omission of breakfast. Participants will consume water within 15 min, the individual volume of which will be calculated based on the liquid content of the breakfast \[milk (ml)+ orange juice (ml)\].
Study NCT03327727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Agent: VL-2397
Description: VL-2397
Study NCT03327727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Description: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Study NCT03327727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Description: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Study NCT02466022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Bolus 0.1cc/kg Normal Saline over 10 min
Study NCT02466022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intrathecal Fentanyl 10ug
Study NCT02466022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Intrathecal Fentanyl 10ug
Study NCT02466022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0-4mg of IV Midazolam prn for rescue sedation
Study NCT02466022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: 0-4mg of IV Midazolam prn for rescue sedation
Study NCT01428648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ballroom Dancing Classes
Description: bi-weekly, 12-Week ballroom dance classes
Study NCT02669888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo naturalis ointment
Description: Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
Study NCT02669888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
Study NCT00853203 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
Study NCT00853203 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Written survey taking about 1 hour.
Study NCT04091139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified protocol for adolescents (UP-A)
Description: The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians.
Study NCT00853203 — intervention group
Intervention type: OTHER
Intervention: Electronically Activated Recorder (EAR)
Description: Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
Study NCT00853203 — intervention group
Intervention type: BEHAVIORAL
Intervention: Group Meetings
Description: 12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
Study NCT00853203 — intervention group
Intervention type: BEHAVIORAL
Intervention: Written Materials
Description: Written educational materials plus community resource information.
Study NCT04562714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Flash Glucose Monitor
Description: The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.
Study NCT04562714 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes self-management education
Description: The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning.
Study NCT04562714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education
Description: The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning.
Study NCT04091139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
Study NCT02235493 — intervention group
Intervention type: BIOLOGICAL
Intervention: Retrospective Case Only
Study NCT05462665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory training
Description: theory training
Study NCT00593684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Alginate
Description: This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
Study NCT05462665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory and simulation training
Description: theory and simulation training
Study NCT01935817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex
Study NCT01935817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02437591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fidaxomicin
Description: oral
Study NCT04101643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Eligible patients receive subcutaneous injections of evolocumab 420 mg
Study NCT04584060 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: ERAS protocols
Description: ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter
Study NCT04584060 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Early oral feeding
Description: Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward
Study NCT04584060 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Prophylaxis against DVT
Description: Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
Study NCT03936855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct composite resin
Description: For both groups: The teeth will have the enamel surface conditioned with 37% phosphoric acid. For the restorative procedure, the same adhesive system will be used~GROUP ACTIVE COMPARATOR~1. Insert resin-modified glass ionomer cement into the pulp chamber;~2. Complete the restoration by incremental technique using conventional composite resin in increments of 2mm;~EXPERIMENTAL GROUP~1. Insert Bulk Fill composite inside the pulp chamber to the height of 5 mm;~2. Complete the insertion of the Bulk Fill resin to the limit of the caval surface angle in the occlusal
Study NCT03936855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct composite resin
Description: For both groups: The teeth will have the enamel surface conditioned with 37% phosphoric acid. For the restorative procedure, the same adhesive system will be used~GROUP ACTIVE COMPARATOR~1. Insert resin-modified glass ionomer cement into the pulp chamber;~2. Complete the restoration by incremental technique using conventional composite resin in increments of 2mm;~EXPERIMENTAL GROUP~1. Insert Bulk Fill composite inside the pulp chamber to the height of 5 mm;~2. Complete the insertion of the Bulk Fill resin to the limit of the caval surface angle in the occlusal
Study NCT02820623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-report
Study NCT02820623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chart-Stimulated Recall
Study NCT02820623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Rehearsal
Study NCT03269149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Tango Dance
Description: 20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.
Study NCT03269149 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational lectures
Description: Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q\&A will be encouraged.
Study NCT00889733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) Cisplatin
Description: For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
Study NCT02842125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-P53
Description: Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
Study NCT02842125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Oral metronomic chemotherapeutic agent
Study NCT02842125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
Study NCT02842125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opdivo
Description: Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
Study NCT00675519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Description: Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
Study NCT03711825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYN-057
Description: Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
Study NCT03711825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Assessment (MRI)
Description: Imaging assessments \[MRI\] will be performed on specified days according to protocol
Study NCT03711825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Assessment (U/S)
Description: Imaging assessments (abdominal U/S) will be performed on specified days according to protocol
Study NCT01256372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP214
Description: AP214
Study NCT01256372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; intravenous infusion
Study NCT02281214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample, biopsy
Description: Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
Study NCT02490878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV
Study NCT02490878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: IV
Study NCT02490878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: IV
Study NCT02931240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revivent TC
Description: Treatment of LV scar
Study NCT02727647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVIII
Description: FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
Study NCT02727647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVIII
Description: FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
Study NCT02431832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin tab
Study NCT01114217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol
Study NCT02213224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
Study NCT02213224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
Study NCT00684320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Disengagement Training (ADT)
Description: Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
Study NCT00684320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Condition
Description: The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
Study NCT02213224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
Study NCT04538534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicardipine
Description: To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
Study NCT01792258 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous tracheostomy
Description: Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
Study NCT00669955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole, amoxicillin, clarithromycin
Description: Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
Study NCT00669955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole
Description: Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
Study NCT02943681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Study NCT00367406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma 3 nail versus ACE trochanteric nail
Description: Comparing Gamma 3 nail versus ACE trochanteric nail